ES2571879T3 - Moléculas de una sola cadena de TNFSF - Google Patents

Moléculas de una sola cadena de TNFSF

Info

Publication number
ES2571879T3
ES2571879T3 ES13152482T ES13152482T ES2571879T3 ES 2571879 T3 ES2571879 T3 ES 2571879T3 ES 13152482 T ES13152482 T ES 13152482T ES 13152482 T ES13152482 T ES 13152482T ES 2571879 T3 ES2571879 T3 ES 2571879T3
Authority
ES
Spain
Prior art keywords
single chain
tnf family
tnfsf
chain molecules
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13152482T
Other languages
English (en)
Inventor
Oliver Hill
Christian Gieffers
Meinolf Thiemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apogenix AG
Original Assignee
Apogenix AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41165705&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2571879(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apogenix AG filed Critical Apogenix AG
Application granted granted Critical
Publication of ES2571879T3 publication Critical patent/ES2571879T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Un polipéptido de fusión de cadena sencilla que comprende: (i) un primer dominio de citoquinas de la familia de TNF soluble, (ii) un primer enlazador peptídico, (iii) un segundo dominio de citoquinas de la familia TNF soluble, (iv) un segundo enlazador peptídico, y (v) un tercer dominio de citoquinas de la familia TNF soluble, en donde el polipéptido de fusión es sustancialmente no-agregante, y en donde los dominios de citoquinas de la familia TNF (i), (iii) y (v) son dominios LIGHT humanos solubles, que comprenden una secuencia de aminoácidos que parte de los aminoácidos 93, 94 ó 95 de SEQ ID NO: 16.
ES13152482T 2008-07-21 2009-07-18 Moléculas de una sola cadena de TNFSF Active ES2571879T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08013112 2008-07-21

Publications (1)

Publication Number Publication Date
ES2571879T3 true ES2571879T3 (es) 2016-05-27

Family

ID=41165705

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13152482T Active ES2571879T3 (es) 2008-07-21 2009-07-18 Moléculas de una sola cadena de TNFSF
ES09780803.4T Active ES2538122T3 (es) 2008-07-21 2009-07-18 Moléculas de una sola cadena de TNFSF

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09780803.4T Active ES2538122T3 (es) 2008-07-21 2009-07-18 Moléculas de una sola cadena de TNFSF

Country Status (14)

Country Link
US (10) US8450460B2 (es)
EP (4) EP2806029B1 (es)
JP (5) JP5674155B2 (es)
CA (3) CA3092223C (es)
CY (1) CY1116288T1 (es)
DK (2) DK2310509T3 (es)
ES (2) ES2571879T3 (es)
HR (1) HRP20150425T1 (es)
HU (1) HUE025236T2 (es)
PL (2) PL2310509T3 (es)
PT (1) PT2310509E (es)
SI (1) SI2310509T1 (es)
SM (1) SMT201500135B (es)
WO (1) WO2010010051A1 (es)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3097926T (pt) * 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
US8450460B2 (en) 2008-07-21 2013-05-28 Apogenix Gmbh Single-chain TNFSF fusion polypeptides
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
CA2831820C (en) * 2011-04-01 2021-05-25 Universitat Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
WO2013037090A1 (zh) * 2011-09-16 2013-03-21 北京沙东生物技术有限公司 包含trail/apo2l环化变构体的融合蛋白及其编码基因与应用
MY201293A (en) 2012-01-12 2024-02-15 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
US9127081B2 (en) * 2012-05-10 2015-09-08 Washington University Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
EP2861616A1 (en) * 2012-06-13 2015-04-22 Scil Proteins GmbH Human fusion proteins comprising single chain tnfalpha and targeting domains
JP2016504045A (ja) 2013-01-09 2016-02-12 ザ ユニバーシティー オブ マイアミＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ ＴＬ１Ａ−Ｉｇ融合タンパク質を用いる制御性Ｔ細胞の制御のための組成物及び方法
SG11201600168UA (en) 2013-07-19 2016-02-26 Vib Vzw Targeted modified tnf family members
CN104418952B (zh) * 2013-09-04 2017-08-08 上海张江生物技术有限公司 一种用于治疗乳腺癌的抗ErbB2双特异性抗体
WO2015061206A2 (en) 2013-10-21 2015-04-30 North Carolina State University Methods and constructs for compound delivery
NO2776305T3 (es) * 2014-04-23 2018-01-27
MX2020012798A (es) * 2014-11-14 2022-04-07 Hoffmann La Roche Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf.
WO2016112983A1 (en) 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
CA2975362A1 (en) 2015-02-06 2016-08-11 Navigo Proteins Gmbh Egfr binding proteins comprising ubiquitin muteins
US10428149B2 (en) 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
CA2984350A1 (en) * 2015-05-04 2016-11-10 Apogenix Ag Single-chain cd40-receptor agonist proteins
JP6856938B2 (ja) 2015-07-16 2021-04-14 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規な免疫グロブリン結合タンパク質およびアフィニティ精製におけるそれらの使用
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CR20180161A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Anticuerpos biespecíficos para pd1 y tim3
EP3365362A1 (en) * 2015-10-23 2018-08-29 Apogenix AG Single-chain ox40-receptor agonist proteins
AU2016341409B2 (en) * 2015-10-23 2021-02-25 Apogenix Ag Single-chain CD27-receptor agonist proteins
CA3002587A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain light receptor agonist proteins
CN108368511B (zh) * 2015-10-23 2022-12-06 阿珀吉科吉尼科斯股份公司 单链cd137受体激动剂蛋白
WO2017068185A1 (en) 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins
CA3003511A1 (en) 2015-10-28 2017-05-04 Apogenix Ag Single-chain tl1a receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
MX2018011219A (es) * 2016-03-16 2019-01-10 Merrimack Pharmaceuticals Inc Trail diseñado por ingenieria para terapia de cancer.
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
CN109310780A (zh) 2016-05-04 2019-02-05 纳维格蛋白质有限公司 包含肽接头的用于化学部分位点-特异性偶联的靶向化合物
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
AR108468A1 (es) * 2016-05-13 2018-08-22 Medimmune Llc POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
EP3243832A1 (en) * 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
AU2017311541B2 (en) 2016-08-11 2020-08-13 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin-binding proteins
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018114754A1 (en) 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
JP7247091B2 (ja) 2016-12-20 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と４－１ｂｂ（ｃｄ１３７）アゴニストの併用療法
EP3565586A1 (en) 2017-01-06 2019-11-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
TW201837168A (zh) 2017-01-06 2018-10-16 美商艾歐凡斯生物治療公司 以腫瘤壞死因子受體超家族（ｔｎｆｒｓｆ）促效劑使腫瘤浸潤淋巴球（ｔｉｌ）擴增及ｔｉｌ與ｔｎｆｒｓｆ促效劑的治療組合
US20190367579A1 (en) 2017-02-27 2019-12-05 Shattuck Labs, Inc. Tigit- and light-based chimeric proteins
PL3606946T3 (pl) 2017-04-03 2022-11-28 F. Hoffmann-La Roche Ag Immunokoniugaty przeciwciała anty-PD-1 ze zmutowaną IL-2 lub z IL-15
BR112019019821A2 (pt) 2017-04-05 2020-04-22 Hoffmann La Roche anticorpo biespecífico, polinucleotídeo, célula hospedeira procariótica ou eucariótica, métodos de produção do anticorpo biespecífico, de tratamento de um indivíduo que tem câncer ou uma infecção viral crônica e de inibição do crescimento de células de tumor, composição farmacêutica e uso do anticorpo biespecífico
AU2018247931B2 (en) * 2017-04-06 2022-03-03 Universität Stuttgart Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN110832070A (zh) 2017-05-10 2020-02-21 艾欧凡斯生物治疗公司 液体肿瘤来源肿瘤浸润淋巴细胞的扩增及其治疗用途
WO2018226714A1 (en) 2017-06-05 2018-12-13 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
EP3634466A4 (en) 2017-06-06 2021-03-24 Relinia, Inc. MONOCATENARY TNF RECEPTOR 2 AGONIST FUSION PROTEINS
WO2019032945A1 (en) * 2017-08-10 2019-02-14 Oncomed Pharmaceuticals, Inc. CD40 BINDING AGENT AND USES THEREOF
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
AU2018364562A1 (en) * 2017-11-09 2020-06-18 Medimmune, Llc Bispecific fusion polypeptides and methods of use thereof
KR20200100060A (ko) 2017-11-17 2020-08-25 이오반스 바이오테라퓨틱스, 인크. 미세 바늘 흡인물 및 소형 생검물로부터의 til 확장
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
JP2021508104A (ja) 2017-12-15 2021-02-25 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
BR112020013848A2 (pt) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
MX2020008404A (es) 2018-02-13 2020-09-25 Gilead Sciences Inc Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
JP7098741B2 (ja) 2018-03-13 2022-07-11 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
EP3765489A1 (en) 2018-03-13 2021-01-20 F. Hoffmann-La Roche AG Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
CN112513254A (zh) 2018-03-29 2021-03-16 艾欧凡斯生物治疗公司 肿瘤浸润淋巴细胞的制备方法及其在免疫治疗中的用途
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
MX2020011134A (es) 2018-04-27 2020-11-11 Iovance Biotherapeutics Inc Proceso cerrado para expansion y edicion de genes de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia.
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN117304130A (zh) 2018-05-14 2023-12-29 吉利德科学公司 Mcl-1抑制剂
AU2019301811B2 (en) 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
WO2020061429A1 (en) 2018-09-20 2020-03-26 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
EP3873884A1 (en) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
PE20211292A1 (es) 2018-11-05 2021-07-20 Iovance Biotherapeutics Inc Procesos para la produccion de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
EP3877512A2 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
JP2022512899A (ja) 2018-11-05 2022-02-07 アイオバンス バイオセラピューティクス，インコーポレイテッド 抗ｐｄ－１抗体に対して不応性のｎｓｃｌｃ患者の治療
US20220033775A1 (en) 2018-11-05 2022-02-03 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathways inhibitors
WO2020131547A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
US20220064245A1 (en) * 2018-12-21 2022-03-03 Vib Vzw Fusion proteins comprising a cytokine and scaffold protein
KR20210136050A (ko) 2019-03-01 2021-11-16 이오반스 바이오테라퓨틱스, 인크. 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
US20220389381A1 (en) 2019-10-25 2022-12-08 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
IL293350A (en) 2019-11-27 2022-07-01 Myst Therapeutics Llc A method for producing tumor-reactive t cells using modulatory substances
CA3161104A1 (en) 2019-12-11 2021-06-17 Cecile Chartier-Courtaud Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
CN115427438A (zh) 2020-02-27 2022-12-02 迈斯特治疗公司 肿瘤反应性t细胞的离体富集和扩增的方法及其相关组合物
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
US20230172987A1 (en) 2020-05-04 2023-06-08 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
IL296880A (en) * 2020-05-06 2022-12-01 Navicure Biopharmaceuticals Ltd Fusion proteins for immunotherapy against cancer and infectious diseases
US20230212260A1 (en) 2020-05-15 2023-07-06 Apogenix Ag Multi-specific immune modulators
AU2021311034A1 (en) 2020-07-24 2023-02-23 F. Hoffmann-La Roche Ag Method for the expression of an antibody-multimer-fusion
AU2020470781A1 (en) 2020-10-01 2023-05-18 Immunicom, Inc. Reduced leaching of a ligand
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022125941A1 (en) 2020-12-11 2022-06-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
JP2023554395A (ja) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療
CA3202473A1 (en) 2020-12-17 2022-06-23 Friedrich Graf Finckenstein Treatment of cancers with tumor infiltrating lymphocytes
WO2022140797A1 (en) * 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
WO2022187741A2 (en) 2021-03-05 2022-09-09 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions
US20240092856A1 (en) 2021-03-09 2024-03-21 Hoffmann-La Roche Inc. Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
WO2022225981A2 (en) 2021-04-19 2022-10-27 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4340850A1 (en) 2021-05-17 2024-03-27 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202327631A (zh) 2021-07-28 2023-07-16 美商艾歐凡斯生物治療公司 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者
EP4148067A1 (en) 2021-09-08 2023-03-15 F. Hoffmann-La Roche AG Method for the expression of an antibody-multimer-fusion
WO2023049862A1 (en) 2021-09-24 2023-03-30 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
TW202331735A (zh) 2021-10-27 2023-08-01 美商艾歐凡斯生物治療公司 協調用於患者特異性免疫療法之細胞之製造的系統及方法
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023144393A1 (en) * 2022-01-28 2023-08-03 Fundació Centre De Regulació Genòmica Therapeutic cytokines and methods
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573924A (en) * 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
JP3589665B2 (ja) * 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
WO2001025277A1 (en) * 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
DE10122140A1 (de) * 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Rekombinante Fusionsproteine und deren Trimere
IL161708A0 (en) * 2001-11-16 2004-09-27 Pharmexa As Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts
JPWO2005056605A1 (ja) * 2003-12-12 2007-12-06 中外製薬株式会社 ３量体以上の受容体を認識する改変抗体
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
EP1894940A1 (en) * 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
CA2963124C (en) * 2007-07-10 2019-10-15 Apogenix Ag Tnf superfamily collectin fusion proteins
US8450460B2 (en) 2008-07-21 2013-05-28 Apogenix Gmbh Single-chain TNFSF fusion polypeptides
WO2010078966A1 (en) 2009-01-09 2010-07-15 Apogenix Gmbh Fusion proteins forming trimers
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
US10428149B2 (en) 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof
AR108468A1 (es) * 2016-05-13 2018-08-22 Medimmune Llc POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS

Also Published As

Publication number Publication date
US10118953B2 (en) 2018-11-06
CA3092223A1 (en) 2010-01-28
US9359420B2 (en) 2016-06-07
JP2014230545A (ja) 2014-12-11
PT2310509E (pt) 2015-05-19
CA2910512A1 (en) 2010-01-28
US10640543B2 (en) 2020-05-05
ES2538122T3 (es) 2015-06-17
EP2604693A2 (en) 2013-06-19
US8921519B2 (en) 2014-12-30
US8450460B2 (en) 2013-05-28
US20110162095A1 (en) 2011-06-30
US20160272695A1 (en) 2016-09-22
EP2806029A1 (en) 2014-11-26
US20140056843A1 (en) 2014-02-27
JP2014230546A (ja) 2014-12-11
JP2011528562A (ja) 2011-11-24
US20190023759A1 (en) 2019-01-24
EP2806029B1 (en) 2016-05-25
CA2910512C (en) 2020-10-27
WO2010010051A1 (en) 2010-01-28
EP2604693B1 (en) 2016-02-24
US20190185534A1 (en) 2019-06-20
JP5674155B2 (ja) 2015-02-25
SMT201500135B (it) 2015-07-09
DK2310509T3 (en) 2015-04-27
PL2604693T3 (pl) 2016-09-30
CA2731388A1 (en) 2010-01-28
SI2310509T1 (sl) 2015-07-31
JP2017128607A (ja) 2017-07-27
US20150110734A1 (en) 2015-04-23
CY1116288T1 (el) 2017-02-08
US20170313752A1 (en) 2017-11-02
JP6694409B2 (ja) 2020-05-13
US11214605B2 (en) 2022-01-04
CA2731388C (en) 2018-05-01
US9725495B2 (en) 2017-08-08
US20150125419A1 (en) 2015-05-07
EP2604693A3 (en) 2014-01-08
EP3103875A1 (en) 2016-12-14
EP2310509B1 (en) 2015-01-21
JP6140117B2 (ja) 2017-05-31
US20170081381A1 (en) 2017-03-23
US10519208B2 (en) 2019-12-31
EP2310509A1 (en) 2011-04-20
PL2310509T3 (pl) 2015-08-31
DK2604693T3 (en) 2016-05-30
HRP20150425T1 (hr) 2015-06-05
US9340599B2 (en) 2016-05-17
JP2017029158A (ja) 2017-02-09
JP6046089B2 (ja) 2016-12-14
US20200247860A1 (en) 2020-08-06
CA3092223C (en) 2023-01-03
HUE025236T2 (en) 2016-03-29

Similar Documents

Publication Publication Date Title
ES2571879T3 (es) Moléculas de una sola cadena de TNFSF
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
CO6190536A2 (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores
PE20100738A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
CY1117351T1 (el) Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης
ES2691539T3 (es) Luciferasas de Oplophorus sintéticas con mayor emisión de luz
IN2014CN02050A (es)
NO20063026L (no) Antistoffer
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
NZ600732A (en) Oxyntomodulin peptide analogue
NZ611324A (en) Il-17 binding proteins
MX2009012609A (es) Composiciones y metodos para producir proteinas de fusion bioactivas.
ES2668967T3 (es) Inmunógenos de Escherichia coli con solubilidad mejorada
MX2020011391A (es) Anticuerpo bcma humanizado y linfocitos t car-bcma.
PE20091067A1 (es) Variantes de peptidos natriureticos de tipo c
NZ600731A (en) Oxyntomodulin peptide analogue
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
ES2507094T3 (es) Proteína específica del timo
ES2421719T3 (es) Antígeno de gliadina recombinante desamidada
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
NZ609216A (en) Anticancer fusion protein
ES2531372T3 (es) Enzimas de procesamiento fusionadas a marcadores de proteínas básicas